Daniel Shames - 26 Feb 2026 Form 4 Insider Report for Mereo BioPharma Group plc (MREO)

Role: Director
Signature: /s/ Christine Fox, by power of attorney
Issuer symbol: MREO
Transactions as of: 26 Feb 2026
Net transactions value: $0
Form type: 4
Filing time: 27 Feb 2026, 16:30:24 UTC
Previous filing: 06 Feb 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Shames Daniel	Director	C/O MEREO BIOPHARMA GROUP PLC, 4TH FLOOR, ONE CAVENDISH PLACE, LONDON, UNITED KINGDOM	/s/ Christine Fox, by power of attorney	27 Feb 2026	0002005702

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MREO	Share Options (Right to buy)	Award	$0	+66,000		$0.000000	66,000	26 Feb 2026	American Depositary Shares	66,000	$0.3900	Direct	F1, F2
transaction	MREO	Deferred Restricted Stock Units	Award		+96,163			96,163	26 Feb 2026	American Depository Shares	96,163		Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Vests in substantially equal monthly installments over a one year period from the February 26, 2026 grant date.
F2	Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.
F3	Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service.